Lupus systémique
Veille bibliographique : Lupus systémique
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| TACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.Arthritis Rheumatol. 2014 Nov;66(11):3096-104 | Lire le résumé |
| Al Maimouni H et al. Switching treatment between mycophenolate mofetil and azathioprine in lupus patients: indications and outcomes. Arthritis Care Res (Hoboken). 2014 Dec;66(12):1905-9 | Lire le résumé |
| Sciascia S et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res (Hoboken). 2014 Dec;66(12):1915-20. | Lire le résumé |
| Tamirou F et al. and the MAINTAIN Nephritis Trial Group. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2015 Mar 10. | Lire le résumé |
| Nishimura K et al. Neurocognitive impairment in corticosteroid-naive patients with active systemic lupus erythematosus: a prospective study. J Rheumatol. 2015 Mar;42(3):441-8 | Lire le résumé |
| Muniz LF et al. Impact of therapy on metabolic syndrome in young adult premenopausal female lupus patients: Beneficial effect of antimalarial. Arthritis Care Res (Hoboken). 2015 Apr 1 | Lire le résumé |
| Jallouli M et al. Plaquenil Lupus Systemic Study Group. Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic lupus Erythematosus. Arthritis Rheumatol. 2015 Mayl;67(8):2176-2184. | Lire le résumé |
| Quinlan C et al. The vascular phenotype of children with systemic lupus erythematosus. Pediatr Nephrol. 2015 May 23 | Lire le résumé |
| Dall'Era M et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the euro-lupus nephritis cohort. Arthritis Rheumatol. 2015 May;67(5):1305-13. | Lire le résumé |
| Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 2015 Sep;27(5):448-53. | Lire le résumé |
| Durcan L et al. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol. 2015 Nov; 42(11):2092-7 | Lire le résumé |
| Hui-Yuen JS et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol. 2015 Dec;42(12):2288-95 | Lire le résumé |
| Kalunian KC et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. janv 2016;75(1):196‑202. | Lire le résumé |
| Mok CC et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. janv 2016;75(1):30‑6. | Lire le résumé |
| Lee JY et al. Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol Hoboken NJ. janv 2016;68(1):184‑90 | Lire le résumé |
| Pereira KMC et al. Low C4, C4A and C4B gene copy numbers are stronger risk factors for juvenile-onset than for adult-onset systemic lupus erythematosus. Rheumatol Oxf Engl. 22 janv 2016 | Lire le résumé |
| Isenberg DA et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, doubleblind, placebo-controlled study. Ann Rheum Dis. févr 2016;75(2):323‑31. | Lire le résumé |
| Merrill JT et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. févr 2016;75(2):332‑40. | Lire le résumé |
| Tselios K et al. Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study. J Rheumatol. mars 2016;43(3):552‑8. | Lire le résumé |
| Tamirou F et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. mars 2016;75(3):526‑31. | Lire le résumé |
| Gomes RC et al. Features of 847 Childhood-Onset Systemic. Lupus Erythematousus Patients in Three Age Groups at Diagnosis: A Brazilian Multicenter Study. Arthritis Care Res. 25 mars 2016 | Lire le résumé |
| Wallace DJ et al. Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. Arthritis Care Res. avr 2016;68(4):534‑43. | Lire le résumé |
| Banchereau R et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 21 avr 2016;165(3):551‑65. | Lire le résumé |
| Medina-Quiñones CV et al. Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period. Arthritis Care Res. juill 2016;68(7):981‑7. | Lire le résumé |
| Rovin BH et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Arthritis Rheumatol Hoboken NJ. sept 2016;68(9):2174‑83. | Lire le résumé |
| Wallace DJ et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II doseranging randomised controlled trial. Ann Rheum Dis. 26 sept 2016 | Lire le résumé |
| Michel M et al. A Randomized and Double-Blind Controlled Trial Evaluating the Safety and Efficacy of Rituximab for Warm Auto-Immune Hemolytic Anemia in Adults (the RAIHA study). Am J Hematol. 3 oct 2016 | Lire le résumé |
| Vinet É et al. Brief Report: Causes of Stillbirths in Women With Systemic Lupus Erythematosus. Arthritis Rheumatol Hoboken NJ. oct 2016;68(10):2487‑91 | Lire le résumé |
| Khamashta M et al. Sifalimumab, an antiinterferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. nov 2016;75(11):1909‑16 | Lire le résumé |
| Singh AG et al. Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Cutaneous Lupus Erythematosus: A Population-Based Cohort Study. Arthritis Care Res. nov 2016;68(11):1664‑70 | Lire le résumé |
| Hoshino A et al. Abnormal hematopoeisis and autoimmunity in human subjects with germline IKZF1 mutations. J Allergy Clin Immunol. 2016 Dec 1 | Lire le résumé |
| Ziegelasch M et al. Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. Arthritis Res Ther. 2016 Dec 3;18(1):289 | Lire le résumé |
| Palmsten K et al. Medication use among pregnant women with systemic lupus erythematosus and general population comparators. Rheumatology (Oxford). 2016 Dec 24. | Lire le résumé |
| Cardoso F. Autoimmune choreas. J Neurol Neurosurg Psychiatry. 2016 Dec 1. pii: jnnp-2016-314475. | Lire le résumé |
| Werth Victoria P. et al. “Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-γ Antibody, in Subjects with Discoid Lupus Erythematosus.” Arthritis & Rheumatology (Hoboken, N.J.), January 24, 2017. | Lire le résumé |
| Sciascia, S. et al. “Efficacy of Belimumab on Renal Outcomes in Patients with Systemic Lupus Erythematosus: A Systematic Review.” Autoimmunity Reviews, January 29, 2017. doi:10.1016/j.autrev.2017.01.010. | Lire le résumé |
| Kahwage PP et al. Uveitis in childhood-onset systemic lupus erythematosus patients: a multicenter survey. Clin Rheumatol. 2017 Jan 9. | Lire le résumé |
| Iaccarino L, et al. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2017 Jan;69(1):115-123. | Lire le résumé |
| Sopeña B et al. Clinical association between Kikuchi ׳s disease and systemic lupus erythematosus: A systematic literature review. Semin Arthritis Rheum. 2017 Jan 29. | Lire le résumé |
| Furie et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69(2):376-386 | Lire le résumé |
| Ahn SS et al. In-hospital mortality in febrile lupus patients based on 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome. Semin Arthritis Rheum. 2017 Feb 8 | Lire le résumé |
| Tamirou F et al. The low-dose intravenous cyclophosphamide Euro-Lupus regimen does not impact the ovarian reserve, as measured by serum anti-Müllerian hormone levels. Arthritis Rheumatol Hoboken NJ. 2017 Feb 24 | Lire le résumé |
| Bundhun PK et al. Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: A meta-analysis of studies published between years 2001-2016. J Autoimmun. 2017 Feb 27 | Lire le résumé |
| Asgari N et al. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. Mult Scler Houndmills Basingstoke Engl. 2017 Mar 1 | Lire le résumé |
| Arkema EV et al. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis. 2017 Apr 11 | Lire le résumé |
| Steri M et al. Overexpression of the Cytokine BAFF and Autoimmunity Risk. N Engl J Med. 2017 27;376(17):1615–26. | Lire le résumé |
| Ordi-Ros J et al. Entericcoated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017 Apr 27 | Lire le résumé |
| Reddy V et al. Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins. Arthritis Care Res. 2017 Jun;69(6):857–66. Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins. Arthritis Care Res. 2017 Jun;69(6):857–66 | Lire le résumé |
| van der Meulen PM et al. Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus. Rheumatol Oxf Engl. 2017 Apr 27 | Lire le résumé |
| Barbhaiya M et al. Race/Ethnicity and Cardiovascular Events among Patients with Systemic Lupus Erythematosus. Arthritis Rheumatol Hoboken NJ. 2017 Jun 9 | Lire le résumé |
| Bialas AR et al. Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature. 2017 Jun 22;546(7659):539–43 | Lire le résumé |
| Md Yusof MY et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017 Jul 6 | Lire le résumé |
| Barsalou J et al. Prenatal exposure to antimalarials decreases the risk of cardiac but not non-cardiac neonatal lupus: a single-centre cohort study. Rheumatol Oxf Engl. 2017 Jun 8 | Lire le résumé |
| Retour sur une année d’essais thérapeutiques dans le LS - Août 2017 | Lire le résumé |
| Yelin E et al. A Prospective Study of the Impact of Current Poverty, History of Poverty, and Exiting Poverty on Accumulation of Disease Damage in Systemic Lupus Erythematosus. Arthritis Rheumatol Hoboken NJ. 2017 Aug;69(8):1612–22 | Lire le résumé |
| Kaplowitz ET et al. Socioeconomic Status Contributes to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes among Women with Systemic Lupus Erythematosus. Arthritis Care Res. 2017 May 8 | Lire le résumé |
| Gergianaki I et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis. 2017 Aug 5 | Lire le résumé |
| Martin M et al. [Systemic lupus erythematosus and lymphopenia: Clinical and pathophysiological features]. Rev Med Interne. 2017 Sep;38(9):603–13. | Lire le résumé |
| Hachulla E et al. Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry. Chest. 2017 Aug 26 | Lire le résumé |
| Fu R et al. Podocyte Activation of NLRP3 Inflammasomes Contributes to the Development of Proteinuria in Lupus Nephritis. Arthritis Rheumatol Hoboken NJ. 2017 Aug;69(8):1636–46 | Lire le résumé |
| Dall’Era M et al. The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. Arthritis Rheumatol Hoboken NJ. 2017 Oct;69(10):1996–2005 | Lire le résumé |
| Izmirly PM et al. The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. Arthritis Rheumatol Hoboken NJ. 2017 Oct;69(10):2006–17 | Lire le résumé |
| Bennett MR. et al. Effects of age and gender on reference levels of biomarkers comprising the pediatric Renal Activity Index for Lupus Nephri tis (p-RAIL). Pediatr Rheumatol Online J. 2017 Oct 13;15(1):74. | Lire le résumé |
| Zhang F. et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018 Jan 2. | Lire le résumé |
| Hogan J et al. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol. 2018 Jan;33(1):111-116. | Lire le rLire le résumé |
| K. Sacré et al. Impaired long-term immune protection following pneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupus erythematosus Ann Rheum Dis, published on February 14, 2018 | Lire le résumé |
| Richard Furie et al. Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus : a continuation of the Phase 3 united States BLISS-76 trial. Arthritis and Rheumatology published online February 2, 2018 | Lire le résumé |
| Mimi Kim et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid syndrome Ann Rheum Dis published on January 25, 2018 | Lire le résumé |
| Zhi-Wei Lai et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single - arm, open - label, phase 1/2 trial. The Lancet, published online March 15, 2018 | Lire le résumé |
| Ingeborg M. Bajema et al. Revision of the International Society of Nephrology / Renal Pathology Society classification for lupus nephritis: classification of definitions, and modified Nat ional Institutes of health activity and chronicity indices. Kidney Int published online 16 February 2018 | Lire le résumé |
| Cheng LE, Amoura Z, Cheah B, Hiepe F, Sullivan BA, Zhou L, et al. A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis & Rheumatology, 2018 March 7 | Lire le résumé |
| Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, et al. Efficacy and safety of subcutaneous belimumab in anti-dsDNA-positive, hypocomplementemic patients with systemic lupus erythamatosus, Arthritis & Rheumatology, 2018 April 18 | Lire le résumé |
| Eudy AM, Siega-Riz AM, Engel SM, Franceschini N, Howard AG, Clowse MEB, et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2018 February 20 | Lire le résumé |
| Autoimmune une Diseases in Patients with Cutaneous Lupus Erythematosis, Elaine Kunzler, Linda Hynan and benjamin Chong, JAMA Dermatology, published online May2, 2018 | Lire le résumé |
| Rashidi A, Fisher SI. Clinical Images: Lupus erythematosus cell. Arthritis & Rheumatology. 2018 May 14 Nakamura H, Fujieda Y, Yasuda S, Nakai M, Atsumi T. Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus Erythematosus. Ann Intern Med. 2018 May 1; Sciascia Sciascia SS, Rubini E, Radin M, Cecchi I, Rossi D, Roccatello D. Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. Annals of the Rheumatic Diseases. 2018 May 18; annrheumdis-2018-213496. | Lire le résumé |
| Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L, et al. Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Annals of the Rheumatic Diseases. 2018 May 5;annrheumdis-2017- 212732 | Lire le résumé |
| Estrada K, Whelan CW, Zhao F, Bronson P, Handsaker RE, Sun C, et al. A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nature Communications. 2018 Dec | Lire le résumé |
| Md Yusof MY, Psarras A, El-Sherbiny YM, Hensor EMA, Dutton K, Ul-Hassan S, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Annals of the Rheumatic Diseases. 2018 Jun 21;annrheumdis-2018-213386. | Lire le résumé |
| Londoño Jimenez A, Mowrey WB, Putterman C, Buyon J, Goilav B, Broder A. Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated with Tubulointerstitial Inflammation and Renal Scarring. Arthritis & Rheumatology [Internet]. 2018 May 31 | Lire le résumé |
| Kato Y, Park J, Takamatsu H, Konaka H, Aoki W, Aburaya S, et al. Apoptosis-derived membrane vesicles drive the cGAS–STING pathway and enhance type I IFN production in systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2018 Jun 26;annrheumdis-2018-212988. | Lire le résumé |
| Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 2018 Jul;392(10143):222–31. | Lire le résumé |
| Mosca M, Costenbader KH, Johnson SR, Lorenzoni V, Sebastiani GD, Hoyer BF, et al. How Do Patients with Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. Arthritis & Rheumatology [Internet]. 2018 Jul 23 [cited 2018 Aug 28] | Lire le résumé |
| De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney International [Internet]. 2018 Jul [cited 2018 Aug 28] | Lire le résumé |
| De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney International [Internet]. 2018 Jul [cited 2018 Aug 28] | Lire le résumé |
| Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH, Choi HK. All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease due to Lupus Nephritis from 1995 to 2014. Arthritis & Rheumatology [Internet]. 2018 Sep 18 [cited 2018 Sep 26]; Available from: http://doi.wiley.com/10.1002/art.40729 Roberts AL, Kubzansky LD, Malspeis S, Feldman CH, Costenbader KH. Association of Depression With Risk of Incident Systemic Lupus Erythematosus in Women Assessed Across 2 Decades. JAMA Psychiatry [Internet] 2018 Sep 12 [cited 2018 Sep 26]; Available from: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2018.2462 Fardet L, Nazareth I, Petersen I. Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer’s disease: a population-based cohort study. Annals of the Rheumatic Diseases. 2018 Sep 5;annrheumdis-2018-214016. | Lire le résumé |
| Yap DYH, Tam CH, Yung S, Wong S, Tang CSO, Mok TMY, et al. Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. Nephrology Dialysis Transplantation [Internet]. 2018 Sep 11 [cited 2018 Sep 26]; Available from: https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfy284/5094973 | Lire le résumé |
| van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. The Lancet [Internet]. 2018 Sep [cited 2018 Sep 27]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673618321676 | Lire le résumé |
| Rovin BH, Solomons N, Pendergraft WF, Dooley MA, Tumlin J, Romero-Diaz J, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney International [Internet]. 2018 Nov [cited 2018 Nov 28]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0085253818306288 | Lire le résumé |
| Gaffar RPineau CA, Bernatsky S, Scott S, Vinet E. Risk of Ocular Anomalies in Children Exposed in Utero to Antimalarials: A Systematic Literature Review. Arthritis Care & Research [Internet]. 2018 Nov 12 [cited 2018 Nov 28]; Available from: http://doi.wiley.com/10.1002/acr.23808 | Lire le résumé |
| Kelley BP, Corrigan JJ, Patel SC, Griffith BD. Neuropsychiatric Lupus with Antibody-Mediated Striatal Encephalitis. American Journal of Neuroradiology [Internet]. 2018 Nov 22 [cited 2018 Nov 28]; Available from: http://www.ajnr.org/lookup/doi/10.3174/ajnr.A5842 | Lire le résumé |
| Hanly JGLi Q, Su L, Urowitz MB, Gordon C, Bae S-C, et al. Psychosis in Systemic Lupus Erythematosus. Arthritis & Rheumatology [Internet]. 2018 Oct 30 [cited 2018 Nov 28]; Available from: http://doi.wiley.com/10.1002/art.40764 | Lire le résumé |
| Sciascia S, Yazdany J, Dall’Era M, Fenoglio R, Radin M, Aggarwal I, et al. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Annals of the Rheumatic Diseases. 2018 Dec 14;annrheumdis-2018-214559 | Lire le résumé |
| Giannakou I, Chatzidionysiou K, Magder LS, Györi N, van Vollenhoven R, Petri MA. Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. Lupus Science & Medicine. 2018 Nov;5(1):e000287 | Lire le résumé |
| Hasni S, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Joyal E, et al. Safety and Tolerability of Omalizumab, A Randomized Clinical Trial of Humanized anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus ( STOP LUPUS ). Arthritis & Rheumatology [Internet]. 2018 Dec 29 [cited 2019 Jan 22]; Available from: http://doi.wiley.com/10.1002/art.40828 | Lire le résumé |
| Scherlinger M, Carcaud C, Truchetet M-E, Barnetche T, Duffau P, Couzi L, et al. Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study. Annals of the Rheumatic Diseases. 2019 Jan 4;annrheumdis-2018-214833 | Lire le résumé |
| Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, et al. Long-Term Prognosis of Patients with Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: CSTAR-PAH Cohort Study. European Respiratory Journal. 2019 Jan 11;1800081 | Lire le résumé |
| Wither JE, Prokopec SD, Noamani B, Chang N-H, Bonilla D, Touma Z, et al. Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms. Zhou X, editor. PLOS ONE. 2018 May 9; 13(5):e0196117 | Lire le résumé |
| Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. Safety and efficacy of belimumab plus standard therapy for up to 13 years in patients with systemic lupus erythematosus. Arthritis & Rheumatology [Internet]. 2019 Feb 16 [cited 2019 Feb 19]; Available from: http://doi.wiley.com/10.1002/art.40861 | Lire le résumé |
| Furie R, Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. Journal of Clinical Investigation [Internet]. 2019 Feb 18 [cited 2019 Feb 19]; Available from: https://www.jci.org/articles/view/124466 | Lire le résumé |
| Jorge A, Jorge A, Wallace ZS, Lu N, Zhang Y, Choi HK. Renal Transplantation and Survival Among Patients With Lupus Nephritis: A Cohort Study. Annals of Internal Medicine. 2019 Feb 19;170(4):240 | Lire le résumé |
| Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, et al. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 28 janv 2019;annrheumdis-2018-214685. | Lire le résumé |
| Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 29 mars 2019;annrheumdis-2019-215089 | Lire le résumé |
| Li TH, Lai C-C, Wang W-H, Chen W-S, Tsao Y-P, Tsai C-Y, et al. Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan. Ann Rheum Dis. 6 avr 2019;annrheumdis-2018-214844 | Lire le résumé |
| Cassia MA, Alberici F, Jones RB, Smith RM, Casazza G, Urban ML, et al. Rituximab as maintenance treatment for systemic Lupus Erythematosus: a multicentre observational study of 147 patients. Arthritis Rheumatol [Internet]. 18 mai 2019 [cité 28 mai 2019]; Disponible sur: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40932 | Lire le résumé |
| Sethi S, Madden BJ, Debiec H, Charlesworth MC, Gross L, Ravindran A, et al. Exostosin 1/Exostosin 2–Associated Membranous Nephropathy. J Am Soc Nephrol. 6 mai 2019;ASN.2018080852 | Lire le résumé |
| Wincup C, Menon M, Smith E, Schwartz A, Isenberg D, Jury EC, et al. Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. Ann Rheum Dis. 28 mars 2019;annrheumdis-2019-215200 | Lire le résumé |
| Barraclough M, McKie S, Parker B, Jackson A, Pemberton P, Elliott R, et al. Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes. Ann Rheum Dis. juill 2019;78(7):934 40 | Lire le résumé |
| Tani C, Elefante E, Signorini V, Zucchi D, Lorenzoni V, Carli L, et al. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. RMD Open. juin 2019;5(2):e000916. | Lire le résumé |
| Lim SS, Helmick CG, Bao G, Hootman J, Bayakly R, Gordon C, et al. Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus — Fulton and DeKalb Counties, Georgia, 2002–2016. MMWR Morb Mortal Wkly Rep. 10 mai 2019;68(18):419‐22 | Lire le résumé |
| Mehta B, Luo Y, Xu J, Sammaritano L, Salmon J, Lockshin M, et al. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Ann Intern Med [Internet]. 9 juill 2019 [cité 23 juill 2019]; Disponible sur: http://annals.org/article.aspx?doi=10.7326/M19-0120 | Lire le résumé |
| ThomThomas DEas DE, Lyons JS, Greene BS, Petri MA. Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. Lupus Sci Med. juin 2019;6(1):e000335." | Lire le résumé |
| 1 . Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae S, et al. Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. févr 2019;71(2):281 9 2. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae S-C, et al. Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care Res. oct 2018;70(10):1478 87 3. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae S, et al. Peripheral nervous system disease in Systemic Lupus Erythematosus: Results from an international, inception cohort study. Arthritis Rheumatol [Internet]. 7 août 2019 [cité 27 août 2019] | Lire le résumé |
| 1. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. sept 1997;40(9):1725 1725. 2. Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. août 2012;64(8):2677 86. 3. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey‐Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol [Internet]. 6 août 2019 [cité 27 août 2019] | Lire le résumé |
| He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 19 sept 2019;annrheumdis-2019-215396 | Lire le résumé |
| Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. Arthritis Rheumatol [Internet]. 18 sept 2019 [cité 25 sept 2019] | Lire le résumé |
| Levy R, Briggs L, Silverman E, Pope E, Lara-Corrales I. Cutaneous Sequelae in Neonatal Lupus: A Retrospective Cohort Study. J Am Acad Dermatol [Internet]. oct 2019 [cité 23 oct 2019] | Lire le résumé |
| Duman T, Demirci S, Uluduz D, Kozak HH, Demir S, Mısırlı CH, et al. Cerebral Venous Sinus Thrombosis as a Rare Complication of Systemic Lupus Erythematosus: Subgroup Analysis of the VENOST Study. J Stroke Cerebrovasc Dis. sept 2019;104372 | Lire le résumé |
| van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Fei K, Gordon RM, et al. Maintenance of efficacy and safety of ustekinumab through 1 year in a randomized phase II trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol [Internet]. 25 nov 2019 [cité 19 déc 2019] | Lire le résumé |
| 1. Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. déc 2019;1(4):e208 19 (Lancet Rheumatol) 2. Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 16 janv 2020;382(3):211 21" | Lire le résumé |
| Houssiau FA, Thanou A, Mazur M, Ramiterre E, Gomez Mora DA, Misterska-Skora M, et al. IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis. 23 déc 2019;annrheumdis-2019-216379. | Lire le résumé |
| Figgett WA, Monaghan K, Ng M, Alhamdoosh M, Maraskovsky E, Wilson NJ, et al. Machine learning applied to whole‐blood RNA‐sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus. Clin Transl Immunol [Internet]. janv 2019 [cité 25 févr 2020];8(12) | Lire le résumé |
| Toro-Domínguez D, Lopez-Domínguez R, García Moreno A, Villatoro-García JA, Martorell-Marugán J, Goldman D, et al. Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification. Sci Rep [Internet]. déc 2019 [cité 25 févr 2020];9(1). | Lire le résumé |
| Lockshin MD, Guerra M, Salmon JE. Elective termination of pregnancy in autoimmune rheumatic diseases. Arthritis Rheumatol [Internet]. 12 mars 2020 [cité 26 mars 2020]; | Lire le résumé |
| Fanouriakis A, Kostopoulou M, Cheema K, Anders H-J, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 27 mars 2020;annrheumdis-2020-216924 | Lire le résumé |
| Mok CC, Ho LY, Ying SKY, Leung MC, To CH, Ng WL. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis. 24 mai 2020;annrheumdis-2020-217178. | Lire le résumé |
| Moroni G, Gatto M, Tamborini F, Quaglini S, Radice F, Saccon F, et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis. 5 juin 2020;annrheumdis-2020-216965. | Lire le résumé |
| Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 22 juill 2020;annrheumdis-2020-217101 | Lire le résumé |
| Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, et al. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol. juill 2020;76(3):292‑302 | Lire le résumé |
| Oni L, Wright RD, Marks S, Beresford MW, Tullus K. Kidney outcomes for children with lupus nephritis. Pediatr Nephrol [Internet]. 28 juill 2020 [cité 27 août 2020] | Lire le résumé |
| Atisha‐Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, et al. CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol [Internet]. 4 août 2020 [cité 27 août 2020] | Lire le résumé |
| Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 17 sept 2020;383(12):1117‑28 | Lire le résumé |
| Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N Engl J Med. 17 sept 2020;383(12):1149‑55 | Lire le résumé |
| Huybrechts KF, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol [Internet]. sept 2020 [cité 28 oct 2020]; | Lire le résumé |
| Liu Y, Zhang Y, Wei Y, Yang H. Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. Arch Gynecol Obstet [Internet]. 3 sept 2020 [cité 28 oct 2020]; | Lire le résumé |
| Ceccarelli F, Pirone C, Perricone C, Selntigia A, Orefice V, Pacucci VA, et al. Pregnancy outcome in systemic lupus erythematosus patients: a monocentric cohort analysis. Rheumatology [Internet]. 21 oct 2020 [cité 28 oct 2020]; | Lire le résumé |
| Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, et al. Long‐term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase 2 open‐label extension study. Arthritis Rheumatol [Internet]. 22 nov 2020 [cité 25 nov 2020]; | Lire le résumé |
| Aranow C, Atish-Fregoso Y, Lesser M, Mackay M, Anderson E, Chavan S, et al. Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial. Ann Rheum Dis. 3 nov 2020;annrheumdis-2020-217872 | Lire le résumé |
| Nehar-Belaid D, Hong S, Marches R, Chen G, Bolisetty M, Baisch J, et al. Mapping systemic lupus erythematosus heterogeneity at the single-cell level. Nat Immunol. sept 2020;21(9):1094‑106 | Lire le résumé |
| Robinson GA, Peng J, Dönnes P, Coelewij L, Naja M, Radziszewska A, et al. Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. Lancet Rheumatol. août 2020;2(8):e485‑96. | Lire le résumé |
| Lee YH, Song GG. Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials. Z Für Rheumatol [Internet]. 20 nov 2020 [cité 18 déc 2020] | Lire le résumé |
| Andersson NW, Skov L, Andersen JT. Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology [Internet]. 24 nov 2020 [cité 18 déc 2020]; | Lire le résumé |
| Sheikh SZ, Scheinberg MA, Wei JC-C, Tegzova D, Stohl W, de Toledo RA, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol [Internet]. déc 2020 [cité 26 janv 2021] (The Lancet) | Lire le résumé |
| Haugaard JH, Dreyer L, Ottosen MB, Gislason G, Kofoed K, Egeberg A. Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. J Am Acad Dermatol [Internet]. déc 2020 [cité 23 févr 2021]; | Lire le résumé |
| Chen Y, Huang S, Chen T, Liang D, Yang J, Zeng C, et al. Machine Learning for Prediction and Risk Stratification of Lupus Nephritis Renal Flare. Am J Nephrol. 19 mars 2021;1‑9. | Lire le résumé |
| Yafasova A, Fosbøl EL, Schou M, Baslund B, Faurschou M, Docherty KF, et al. Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus. J Am Coll Cardiol. avr 2021;77(14):1717‑27. | Lire le résumé |
| Leffers HCB, Troldborg A, Voss A, Kristensen S, Lindhardsen J, Kumar P, et al. Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study. Lupus Sci Med. avr 2021;8(1):e000474. | Lire le résumé |
| Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet [Internet]. mai 2021 [cité 25 mai 2021] ; | Lire le résumé |
| Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M, et al. Phase 2, Randomized, Placebo-Controlled Trial of Dapirolizumab Pegol in Patients with Moderate-to-Severe Active Systemic Lupus Erythematosus. Rheumatology [Internet]. 6 mai 2021 [cité 27 mai 2021]; | Lire le résumé |
| Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun [Internet]. déc 2021 [cité 22 juin 2021];12(1) | Lire le résumé |
| Qu J, Li M, Wang Y, Duan X, Luo H, Zhao C, et al. Predicting Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: CSTAR Cohort Study. Arthritis Rheumatol [Internet]. 9 juin 2021 [cité 22 juin 2021] | Lire le résumé |
| Ginzler E, Guedes Barbosa LS, D’Cruz D, Furie R, Maksimowicz‐McKinnon K, Oates J, et al. EMBRACE: Phase 3/4, Randomized, 52‐Week Study of Belimumab Efficacy and Safety in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis Rheumatol. 23 juin 2021;art.41900. | Lire le résumé |
| Tanaka Y, Bae S-C, Bass D, Curtis P, Chu M, DeRose K, et al. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open. juill 2021;7(2):e001629. | Lire le résumé |
| Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 5 août 2021;385(6):567‑9. | Lire le résumé |
| Izmirly PM, Kim MY, Samanovic M, Fernandez‐Ruiz R, Ohana S, Deonaraine KK, et al. Evaluation of Immune Response and Disease Status in SLE Patients Following SARS‐CoV‐2 Vaccination. Arthritis Rheumatol. 4 août 2021;art.41937. | Lire le résumé |
| Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. sept 2021;17(9):515‑32. | Lire le résumé |
| Giani T, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus. 2 oct 2021;096120332110450. | Lire le résumé |
| Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 6 oct 2021;annrheumdis-2021-220920. | Lire le résumé |
| Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, et al. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial. Ann Intern Med. 26 oct 2021;M21-2078. | Lire le résumé |
| 1. Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. sept 2021;S0085253821008620. 2.Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 17 sept 2020;383(12):1117‑28. | Lire le résumé |
| Mejia-Vilet JM, Malvar A, Arazi A, Rovin BH. The lupus nephritis management renaissance. Kidney Int. oct 2021;S0085253821008747. | Lire le résumé |
| Gatto M, Saccon F, Andreoli L, Bartoloni E, Benvenuti F, Bortoluzzi A, et al. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. J Autoimmun. nov 2021;124:102729. | Lire le résumé |
| Giani T, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus. oct 2021;30(12):1955‑65. | Lire le résumé |
| Almeida-Brasil CC, Hanly JG, Urowitz M, Clarke AE, Ruiz-Irastorza G, Gordon C, et al. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 15 déc 2021;annrheumdis-2021-221295. | Lire le résumé |
| Ji L, Xie W, Fasano S, Zhang Z. Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis. Lupus Sci Med. janv 2022;9(1):e000603. | Lire un résumé |
| Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 10 févr 2022;annrheumdis-2021-221478. | Lire le résumé |
| Furie RA, Hough DR, Gaudy A, Ye Y, Korish S, Delev N, et al. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. févr 2022;9(1):e000581. | Lire le résumé |
| Merrill JT, Werth VP, Furie R, van Vollenhoven R, Dörner T, Petronijevic M, et al. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med. 17 mars 2022;386(11):1034‑45. | Lire le résumé |
| Morand EF, Furie RA, Bruce IN, Vital EM, Dall’Era M, Maho E, et al. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol. avr 2022;4(4):e282‑92. | Lire le résumé |
| Meisgen S, Hedlund M, Ambrosi A, Folkersen L, Ottosson V, Forsberg D, et al. Auxilin is a novel susceptibility gene for congenital heart block which directly impacts fetal heart function. Ann Rheum Dis. 25 avr 2022;annrheumdis-2021-221714. | Lire le résumé |
| Duarte-García A, Hocaoglu M, Valenzuela-Almada M, Osei-Onomah SA, Dabit JY, Sanchez-Rodriguez A,et al. Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. Ann Rheum Dis. 16 mai 2022;annrheumdis-2022-222276 | Lire le résumé |
| Fu Q, Wu C, Dai M, Wang S, Xu J, Dai L, et al. Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. Ann Rheum Dis. 4 juill 2022;annrheumdis-2022-222486 | Lire le résumé |
| van Vollenhoven RF, Kalunian KC, Dörner T, Hahn BH, Tanaka Y, Gordon RM, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. 7 juill 2022;annrheumdis-2022-222858 | Lire le résumé |
| Bolognesi MM, Capitoli G, Galimberti S, Cattoretti G, Bajema I, Bruijn JA, et al. Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III/IV. Ann Rheum Dis. 8 août 2022;annrheumdis-2022-222620 | Lire le résumé |
| Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, et al. Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. N Engl J Med. 28 juill 2022;387(4):321‑31 | Lire le résumé |
| Chiou YR, Chang YS, Su CF, Li TH, Lai CC, Hwang DK, et al. Risks of posterior segment ocular ischaemic events in patients with systemic lupus erythematosus: a population-based cohort study in Taiwan. Br J Ophthalmol. 3 août 2022;bjophthalmol-2022-321653 | Lire le résumé |
| Chang LS, Huang PY, Kuo HC, Tu YK, Tseng PT, Liang CS, et al. Diagnostic accuracy of the American College of Rheumatology-1997, the Systemic Lupus International Collaborating Clinics-2012, and the European League Against Rheumatism-2019 criteria for juvenile systemic lupus erythematosus: A systematic review and network meta-analysis. Autoimmun Rev. sept 2022;21(9):103144 | Lire le résumé |
| Jorge AM, Mancini C, Zhou B, Ho G, Zhang Y, Costenbader K, et al. Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares. JAMA [Internet]. 16 sept 2022 [cité 28 sept 2022] | Lire le résumé |
| Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med [Internet]. 15 sept 2022 [cité 29 sept 2022]; Disponible sur: https://www.nature.com/articles/s41591-022-02017-5 | Lire le résumé |
| Petri M, Landy H, Clowse MEB, Gemzoe K, Khamashta M, Kurtinecz M, et al. Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis. 5 oct 2022;annrheumdis-2022-222505. | Lire le résumé |
| Duong MD, Wang S, Schwartz D, Mowrey WB, Broder A, Goilav B. Total cortical interstitial inflammation predicts chronic kidney disease progression in patients with lupus nephritis. Nephrol Dial Transplant. 11 oct 2022;gfac286. | Lire le résumé |
| Wang H, Li T, Sun F, Liu Z, Zhang D, Teng X, et al. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial. RMD Open. oct 2022;8(2):e002686 | Lire le résumé |
| Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, et al. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis Rheumatol. 11 nov 2022;art.42392 | Lire le résumé |
| Melles RB, Jorge AM, Marmor MF, Zhou B, Conell C, Niu J, et al. Hydroxychloroquine Dose and Risk for Incident Retinopathy: A Cohort Study. Ann Intern Med. 17 janv 2023;M22-2453 | Lire le résumé |
| Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial. Arthritis Rheumatol. févr 2023;75(2):242‑52. | Lire le résumé |
| Labouret M, Costi S, Bondet V, Trebossen V, Le Roux E, Ntorkou A, Bartoli S, Auvin S, Bader-Meunier B, Baudouin V, Corseri O, Dingulu G, Ducrocq C, Dumaine C, Elmaleh M, Fabien N, Faye A, Hau I, Hentgen V, Kwon T, Meinzer U, Ouldali N, Parmentier C, Pouletty M, Renaldo F, Savioz I, Rozenberg F, Frémond ML, Lepelley A, Rice GI, Seabra L, Benoist JF, Duffy D, Crow YJ, Ellul P, Melki I. Juvenile Neuropsychiatric Systemic Lupus Erythematosus: Identification of Novel Central Neuroinflammation Biomarkers. J Clin Immunol. 2023 Apr;43(3):615-624 | Lire le résumé |
| Petri M, Bruce IN, Dörner T, Tanaka Y, Morand EF, Kalunian KC, Cardiel MH, Silk ME, Dickson CL, Meszaros G, Zhang L, Jia B, Zhao Y, McVeigh CJ, Mosca M. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023 Mar 25;401(10381):1011-1019. doi: 10.1016/S0140-6736(22)02546-6. Epub 2023 Feb 24. PMID: 36848919. Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, Furie RA, Silk ME, Dickson CL, Meszaros G, Jia B, Crowe B, de la Torre I, Dörner T. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023 Mar 25;401(10381):1001-1010. doi: 10.1016/S0140-6736(22)02607-1. Epub 2023 Feb 24. PMID: 36848918. | Lire le résumé |
| Gomez A, Jägerback S, Sjöwall C, Parodis I. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials. Rheumatol Oxf Engl. 25 mai 2023;kead253 | Lire le résumé |
| Xin-yu Zhao, Shuang-shuang Li, Ying-xin He, Li-jie Yan, Fu Lv, Qi-meng Liang, et al. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis. 1 oct 2023;82(10):1328 | Lire le résumé |
| Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 12 oct 2023;ard-2023-224762 | Lire le résumé |
| Zoshima T, Hara S, Suzuki K, Yoshida M, Konishi M, Hibino S, et al. Long-term outcomes of lupus nephritis with low-level proteinuria: a multicenter, retrospective study. Rheumatol Oxf Engl. 24 nov 023;kead624. | Lire le résumé |
| Rovin BH, Furie RA, Ross Terres JA, Giang S, Schindler T, Turchetta A, et al. Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial. Arthritis Rheumatol. 10 nov 2023;art.42734. | Lire le résumé |
| Katsumata Y, Inoue E, Harigai M, Cho J, Louthrenoo W, Hoi A, et al. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Ann Rheum Dis. 29 févr 2024;ard-2023-225369 | Lire le résumé |
| Li Q, Yang Z, Chen K, Zhao M, Long H, Deng Y, et al. Human-multimodal deep learning collaboration in « precise » diagnosis of lupus erythematosus subtypes and similar skin diseases. J Eur Acad Dermatol Venereol. 15 avr 2024; | Lire le résumé |
| Figueroa-Parra G, Cuéllar-Gutiérrez MC, González-Treviño M, Sanchez-Rodriguez A, Flores-Gouyonnet J, Meade-Aguilar JA, et al. Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: A systematic review and meta-analysis of the control arms of randomized controlled trials. Arthritis Rheumatol. 20 mai 2024; | Lire le résumé |
| Merrill JT, Tanaka Y, D’Cruz D, Vila-Rivera K, Siri D, Zeng X, et al. Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial. Arthritis Rheumatol Hoboken NJ. 24 juin 2024; | Lire le résumé |
| Aranow C, Allaart CF, Amoura Z, Bruce IN, Cagnoli PC, Chatham WW, et al. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Ann Rheum Dis. 19 août 2024;ard-2024-225686. | Lire le résumé |